Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2−/− mice

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|4|1451-1463

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.4, 2015-04, pp. : 1451-1463

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3390-3392

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara   Cho Daniel C  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite

Immunosuppressive minimization with mTOR inhibitors and belatacept

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 8, 2015-08 ,pp. : 921-927

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Development of mTOR Inhibitors: A Focus on Lymphoma

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 103-110

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of Sunitinib Rechallenge in Kidney Cancer: Are mTOR Inhibitors Involved or Is It Only a Matter of Time?

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 295-296

Karger

Access to resources Recommend Favorite